JP2022546572A5 - - Google Patents

Info

Publication number
JP2022546572A5
JP2022546572A5 JP2022514481A JP2022514481A JP2022546572A5 JP 2022546572 A5 JP2022546572 A5 JP 2022546572A5 JP 2022514481 A JP2022514481 A JP 2022514481A JP 2022514481 A JP2022514481 A JP 2022514481A JP 2022546572 A5 JP2022546572 A5 JP 2022546572A5
Authority
JP
Japan
Application number
JP2022514481A
Other languages
Japanese (ja)
Other versions
JP7805287B2 (ja
JPWO2021046331A5 (https=
JP2022546572A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/049377 external-priority patent/WO2021046331A1/en
Publication of JP2022546572A publication Critical patent/JP2022546572A/ja
Publication of JPWO2021046331A5 publication Critical patent/JPWO2021046331A5/ja
Publication of JP2022546572A5 publication Critical patent/JP2022546572A5/ja
Application granted granted Critical
Publication of JP7805287B2 publication Critical patent/JP7805287B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022514481A 2019-09-05 2020-09-04 抗steap1抗体およびその使用 Active JP7805287B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962896415P 2019-09-05 2019-09-05
US62/896,415 2019-09-05
PCT/US2020/049377 WO2021046331A1 (en) 2019-09-05 2020-09-04 Anti-steap1 antibodies and uses thereof

Publications (4)

Publication Number Publication Date
JP2022546572A JP2022546572A (ja) 2022-11-04
JPWO2021046331A5 JPWO2021046331A5 (https=) 2023-09-11
JP2022546572A5 true JP2022546572A5 (https=) 2023-09-11
JP7805287B2 JP7805287B2 (ja) 2026-01-23

Family

ID=74853055

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022514481A Active JP7805287B2 (ja) 2019-09-05 2020-09-04 抗steap1抗体およびその使用

Country Status (9)

Country Link
US (1) US20220348686A1 (https=)
EP (1) EP4025609A4 (https=)
JP (1) JP7805287B2 (https=)
KR (1) KR20220057575A (https=)
CN (1) CN114929743B (https=)
AU (1) AU2020343652A1 (https=)
CA (1) CA3150149A1 (https=)
IL (1) IL291027A (https=)
WO (1) WO2021046331A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20240415888A1 (en) * 2021-10-20 2024-12-19 Memorial Sloan Kettering Cancer Center Anti-tshr multi-specific antibodies and uses thereof
GB202208119D0 (en) * 2022-06-01 2022-07-13 Univ Oslo Hf Anti-steap1 car
CA3261989A1 (en) * 2022-07-22 2024-01-25 Genentech, Inc. ANTI-STEAP1 ANTIGEN-BINDING MOLECULES AND THEIR USES
US20260042860A1 (en) * 2022-08-04 2026-02-12 Memorial Sloan-Kettering Cancer Center Anti-cd24 antibodies and uses thereof
AU2024243972A1 (en) * 2023-04-06 2025-10-23 Memorial Hospital For Cancer And Allied Diseases Il-10 receptor antibodies and methods of use thereof
WO2025042872A1 (en) * 2023-08-21 2025-02-27 Amgen Research (Munich) Gmbh Combination therapy for treating prostate cancer
WO2025042865A1 (en) * 2023-08-21 2025-02-27 Amgen Research (Munich) Gmbh Methods for treating prostate cancer with bispecific antibodies binding steap1xcd3
WO2025128807A1 (en) * 2023-12-13 2025-06-19 Amgen Inc. Radiolabeled compounds for the detection of steap1
CN119113151B (zh) * 2024-08-01 2025-11-18 华中科技大学同济医学院附属同济医院 一种前列腺癌特异性细胞外囊泡荧光探针及其制备方法

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2443996T3 (es) * 2004-04-22 2014-02-21 Agensys, Inc. Anticuerpos y moléculas derivadas de los mismos que se unen a proteínas STEAP-1
CN101573384B (zh) * 2006-10-27 2013-02-20 健泰科生物技术公司 抗体和免疫偶联物及其用途
KR20140116546A (ko) * 2006-10-27 2014-10-02 제넨테크, 인크. 항체 및 면역접합체 및 이들의 용도
GB0917044D0 (en) * 2009-09-29 2009-11-18 Cytoguide As Agents, uses and methods
RU2613886C2 (ru) * 2010-06-03 2017-03-21 Дженентек, Инк. Антитела и иммуноконъюгаты, визуализируемые при помощи иммуно-позитрон-эмиссионной томографии, и способы их применения
BR112014012882A2 (pt) * 2011-11-29 2017-06-13 Genentech Inc método, anticorpo, polinucleotídeo, célula hospedeira, linhagem celular de hibridoma, uso do anticorpo e kit
KR101911438B1 (ko) * 2012-10-31 2018-10-24 삼성전자주식회사 이중 특이 항원 결합 단백질 복합체 및 이중 특이 항체의 제조 방법
US20170043034A1 (en) * 2014-01-24 2017-02-16 Genentech, Inc. Methods of using anti-steap1 antibodies and immunoconjugates
MX2017003123A (es) * 2014-09-12 2017-05-12 Genentech Inc Anticuerpos y conjugados modificados geneticamente con cisteina.
CN113552350B (zh) * 2015-04-21 2024-10-11 基因泰克公司 用于前列腺癌分析的组合物和方法
KR20180023949A (ko) * 2015-06-09 2018-03-07 메모리얼 슬로안-케터링 캔서 센터 인간 hla에 의해 제시된 ebv 잠복성 막 단백질 2a 펩티드에 특이적인 t 세포 수용체-유사 항체 작용제
WO2017055388A2 (en) * 2015-10-02 2017-04-06 F. Hoffmann-La Roche Ag Bispecific t cell activating antigen binding molecules
US11046768B2 (en) * 2017-01-27 2021-06-29 Memorial Sloan Kettering Cancer Center Bispecific HER2 and CD3 binding molecules
SG11201909218RA (en) * 2017-04-03 2019-11-28 Hoffmann La Roche Antibodies binding to steap-1
US12084514B2 (en) * 2017-12-04 2024-09-10 The Board Of Regents Of The University Of Oklahoma Anti-DCLK1 antibodies and chimeric antigen receptors, and compositions and methods of use thereof
EP3938400B1 (en) * 2019-03-11 2025-07-30 Memorial Sloan Kettering Cancer Center Cd22 antibodies and methods of using the same

Similar Documents

Publication Publication Date Title
BR112023012656A2 (https=)
JP2022546572A5 (https=)
BR112021014123A2 (https=)
BR112023009656A2 (https=)
BR112022009896A2 (https=)
BR112021017747A2 (https=)
BR112022024743A2 (https=)
BR112022026905A2 (https=)
BR112023011738A2 (https=)
BR112023004146A2 (https=)
BR112023006729A2 (https=)
BR102021018859A2 (https=)
BR102021015500A2 (https=)
BR112023016292A2 (https=)
BR112023011610A2 (https=)
BR112023011539A2 (https=)
BR112023008976A2 (https=)
BR102021020147A2 (https=)
BR102021018926A2 (https=)
BR102021018167A2 (https=)
BR102021017576A2 (https=)
BR102021016837A2 (https=)
BR102021016551A2 (https=)
BR102021016176A2 (https=)
BR102021015566A2 (https=)